N,N,2-trimethyl-4-phenyldiazenylaniline | 3732-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 偶氮苯
• 英文名称: N,N,2-trimethyl-4-phenyldiazenylaniline
• 英文别名: trans-3-Methyl-4-dimethylamino-azobenzol
• CAS: 3732-90-9
• 化学式: C₁₅H₁₇N₃
• 分子量: 239.32
• InChiKey: FMDTUZFOCQKSFX-WUKNDPDISA-N

物化性质

• 沸点：
  371.98°C (rough estimate)
• 密度：
  1.1092 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4.48
• 重原子数：
  18.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  27.96
• 氢给体数：
  0.0
• 氢受体数：
  3.0

安全信息

• 海关编码：
  2927000090

反应信息

• 作为产物：
  描述：

  N,N-二甲基邻甲苯胺 在 盐酸 、 溶剂黄146 、 氢化铝 作用下， 生成 N,N,2-trimethyl-4-phenyldiazenylaniline
  参考文献：
  名称：

  van Loon,A. et al., Recueil des Travaux Chimiques des Pays-Bas, 1960, vol. 79, p. 977 - 1001

  摘要：

  DOI：

文献信息

• Multi-stage stem cell carcinogenesis
  申请人：Krtolica Ana

  公开号：US20100162416A1

  公开（公告）日：2010-06-24

  The present invention relates to a system of multi-stage stem cell carcinogenesis and a method of generating such multi-stage stem cell carcinogenesis system. Various stages of cancer stem cells can be generated from normal stem cells via mutagenesis. The system of the present invention enables monitoring changes in the ability of cells to transition from one stage of carcinogenesis to another and to identify genetic pathways and molecules that influence carcinogenesis. The present invention also enables a high-throughput and nonbiased screening for targets that preferentially affect cancer stem cells relative to non-cancer stem cells or their derivatives during stem cell carcinogenesis, thus is useful in developing anti-cancer therapeutics.
• US6090414A
  申请人：——

  公开号：US6090414A

  公开（公告）日：2000-07-18
• [EN] MULTI-STAGE STEM CELL CARCINOGENESIS<br/>[FR] CARCINOGENESE DE CELLULES SOUCHES MULTIETAPES
  申请人：STEMLIFELINE INC

  公开号：WO2010037134A2

  公开（公告）日：2010-04-01

  The present invention relates to a system of multi-stage stem cell carcinogenesis and a method of generating such multi-stage stem cell carcinogenesis system. Various stages of cancer stem cells can be generated from normal stem cells via mutagenesis. The system of the present invention enables monitoring changes in the ability of cells to transition from one stage of carcinogenesis to another and to identify genetic pathways and molecules that influence carcinogenesis. The present invention also enables a high-throughput and nonbiased screening for targets that preferentially affect cancer stem cells relative to non-cancer stem cells or their derivatives during stem cell carcinogenesis, thus is useful in developing anti-cancer therapeutics.
• [EN] TREATMENT OF LIVER FAILURE WITH ACTIVATED T REGULATORY CELLS<br/>[FR] TRAITEMENT DE L'INSUFFISANCE HÉPATIQUE AVEC DES LYMPHOCYTES T RÉGULATEURS ACTIVÉS
  申请人：VIERA BIOSCIENCE INC

  公开号：WO2018236988A1

  公开（公告）日：2018-12-27

  Systems, compositions, and methods for the treatment of a liver disorder is disclosed. The systems, compositions, and methods include use of activated T regulatory cells for alleviating, treating, or reducing a liver disorder. The T regulatory cells may be allogeneic T regulatory cells that may be present in an amount of about 5×105 to 2×106 cells. The liver disorder needing treatment may be hepatitis, cirrhosis, chronic liver disease, acute liver disease, or liver failure.